Sleep Apnea in Sickle Cell Disease

NCT ID: NCT03753854

Last Updated: 2022-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-28

Study Completion Date

2021-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite the fact that obstructive sleep apnoea (OSA) is highly prevalent in the sickle cell population, studies focusing on the associations of the two diseases and their common pathophysiological mechanisms are scarce. OSA is one of the most common conditions responsible for hemoglobin desaturation. The nocturnal hemoglobin desaturation occurring in some sickle cell disease (SCD) patients with OSA could trigger hemoglobin S polymerization and red blood cell (RBC) sickling, leading to further blood rheological alterations, hence increasing the risks for VOC. Moreover, OSA has been demonstrated to increase oxidative stress and inflammation in non Sickle Cell Disease (SCD) patients, which, in SCD patients, could increase the risk for complications. Finally, OSA is accompanied by impaired vascular function and autonomic nervous system dysfunction in the general population. Indeed, the presence of OSA in SCD could increase the clinical severity of patients and the frequency of VOC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

sickle cell disease obstructive sleep apnoea vaso-occlusive crisis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SS patients apneic

Homozygous sickle cell patients after one year of continuous positive airway pressure treatment

Each patient will undergo the following:

1. polysomnography and oxygen saturation exam
2. calculation of VOC rate within the two previous years
3. Blood samples
4. Physiological measurements

Group Type EXPERIMENTAL

polysomnography and oxygen saturation exam

Intervention Type DIAGNOSTIC_TEST

Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation

calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment

Intervention Type BIOLOGICAL

calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment

Blood samples

Intervention Type BIOLOGICAL

Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers

Physiological measurements

Intervention Type OTHER

Evaluation of microvascular reactivity and autonomic nervous system activity

Continuous Positive Airway Pressure

Intervention Type OTHER

Continuous Positive Airway Pressure during 1 year

SS patients

Homozygous sickle cell patients

Each patient will undergo the following:

1. polysomnography and oxygen saturation exam
2. calculation of VOC rate within the two previous years
3. Blood samples
4. Physiological measurements

Group Type ACTIVE_COMPARATOR

polysomnography and oxygen saturation exam

Intervention Type DIAGNOSTIC_TEST

Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation

calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment

Intervention Type BIOLOGICAL

calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment

Blood samples

Intervention Type BIOLOGICAL

Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers

Physiological measurements

Intervention Type OTHER

Evaluation of microvascular reactivity and autonomic nervous system activity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

polysomnography and oxygen saturation exam

Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation

Intervention Type DIAGNOSTIC_TEST

calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment

calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment

Intervention Type BIOLOGICAL

Blood samples

Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers

Intervention Type BIOLOGICAL

Physiological measurements

Evaluation of microvascular reactivity and autonomic nervous system activity

Intervention Type OTHER

Continuous Positive Airway Pressure

Continuous Positive Airway Pressure during 1 year

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Homozygous HbS (Hemoglobin S) (SS) patients,
* aged between 15 and 3 months and 50 years old,
* in steady state (i.e. without vaso-occlusive crisis or recent blood transfusion),
* followed by the sickle cell center of the Hospices Civils de Lyon,
* and showing symptoms of OSA.

Exclusion Criteria

* Patients receiving treatment of OSA,
* recent blood transfusion (less than 2 months),
* patients not at steady state (VOC or acute chest syndrome less than 2 months),
* pregnancy.
Minimum Eligible Age

15 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Edouard Herriot

Lyon, , France

Site Status

Centre Léon Berard

Lyon, , France

Site Status

Hôpital de la Croix Rousse

Lyon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Stauffer E, Poutrel S, Cannas G, Gauthier A, Fort R, Bertrand Y, Renoux C, Joly P, Boisson C, Hot A, Peter-Derex L, Pialoux V, PetitJean T, Connes P. Nocturnal Hypoxemia Rather Than Obstructive Sleep Apnea Is Associated With Decreased Red Blood Cell Deformability and Enhanced Hemolysis in Patients With Sickle Cell Disease. Front Physiol. 2021 Sep 24;12:743399. doi: 10.3389/fphys.2021.743399. eCollection 2021.

Reference Type DERIVED
PMID: 34630163 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A03352-51

Identifier Type: OTHER

Identifier Source: secondary_id

69HCL17_0784

Identifier Type: -

Identifier Source: org_study_id